InfanDx AG is a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health. Lead by a team of seasoned industry experts, InfanDx initially focused on the development of a test for the early detection of hypoxic-ischemic encephalopathy.
The Company shifted focus in 2023 to non-invasive prenatal screening. Based on a proprietary in-licensed technology InfanDx aims to take non-invasive prenatal testing beyond the current scope of chromosome copy number variations (aneupolodies) and large structural variations of DNA to testing of microdeletions and point mutations causative to a large number of genetic diseases. The initial focus of InfanDx's product pipeline lies on taking functional newborn screening for common monogenetic conditions, the current standard-of-care, to an early prenatal stage by non-invasive prenatal genetic screening.
The Company is headquartered in Cologne, Germany, with a branch office in Berlin, Germany, and a wholly owned subsidiary in Boston, MA, USA.
aitiologic is an Austrian precision medicine startup developing ai-powered solutions for early disease detection and targeted therapy. aitiologic builds on patented multi-omics technology originally invented at Siemens Healthineers. InfanDx partners with aitiologic for access to this technology in the field of non-invasive prenatal testing and jointly develops with aitiologic the technology platforms for data generation in the lab and cloud-based data interpretation for multiple disease indications, respectively.
For our clinical research we rely on an exceptional network of clinical partners coordinated by Prof. Dr. Dr. Peter Bartmann, Children’s Hospital of the University Hospital Bonn (Germany).
